Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.

Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ.

Kidney Int. 2008 Mar;73(6):684-90. Epub 2007 Dec 19. Review.

2.

CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.

Soos TJ, Meijer L, Nelson PJ.

Drug News Perspect. 2006 Jul-Aug;19(6):325-8. Review.

PMID:
16971968
3.

The CDK inhibitors in cancer research and therapy.

Cicenas J, Valius M.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1409-18. doi: 10.1007/s00432-011-1039-4. Epub 2011 Aug 30. Review.

PMID:
21877198
4.

Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.

Medina M, Castro A.

Curr Opin Drug Discov Devel. 2008 Jul;11(4):533-43. Review.

PMID:
18600569
5.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. Review.

PMID:
20698823
6.
7.

Progress in the evaluation of CDK inhibitors as anti-tumor agents.

McInnes C.

Drug Discov Today. 2008 Oct;13(19-20):875-81. doi: 10.1016/j.drudis.2008.06.012. Epub 2008 Aug 3. Review.

PMID:
18639646
8.

The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.

Palomo V, Perez DI, Gil C, Martinez A.

Curr Med Chem. 2011;18(20):3028-34. Review.

PMID:
21651477
9.

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

Canavese M, Santo L, Raje N.

Cancer Biol Ther. 2012 May;13(7):451-7. doi: 10.4161/cbt.19589. Epub 2012 May 1. Review.

PMID:
22361734
10.

Cyclins and the cyclin-kinase system--their potential roles in nephrology.

Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F.

Nephrol Dial Transplant. 1998 Aug;13(8):1913-6. Review.

PMID:
9719135
11.

Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.

Kockeritz L, Doble B, Patel S, Woodgett JR.

Curr Drug Targets. 2006 Nov;7(11):1377-88. Review.

PMID:
17100578
12.

Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.

Stone A, Sutherland RL, Musgrove EA.

Crit Rev Oncog. 2012;17(2):175-98. Review.

PMID:
22471707
13.
14.

New perspective on the dual functions of indirubins in cancer therapy and neuroprotection.

Wang Y, Hoi PM, Chan JY, Lee SM.

Anticancer Agents Med Chem. 2014;14(9):1213-9. Review.

PMID:
25175685
15.

ATP-noncompetitive inhibitors of CDK-cyclin complexes.

Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E.

ChemMedChem. 2009 Jan;4(1):19-24. doi: 10.1002/cmdc.200800185. Review.

PMID:
19039815
16.

Targeting cyclin-dependent kinases in anti-neoplastic therapy.

Bruyère C, Meijer L.

Curr Opin Cell Biol. 2013 Dec;25(6):772-9. doi: 10.1016/j.ceb.2013.08.004. Epub 2013 Sep 6. Review.

PMID:
24011867
17.

Targeting GSK-3 family members in the heart: a very sharp double-edged sword.

Cheng H, Woodgett J, Maamari M, Force T.

J Mol Cell Cardiol. 2011 Oct;51(4):607-13. doi: 10.1016/j.yjmcc.2010.11.020. Epub 2010 Dec 13. Review.

18.

Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.

Prével C, Kurzawa L, Van TN, Morris MC.

Eur J Med Chem. 2014 Dec 17;88:74-88. doi: 10.1016/j.ejmech.2014.10.003. Epub 2014 Oct 5. Review.

PMID:
25314935
19.

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.

Abate AA, Pentimalli F, Esposito L, Giordano A.

Expert Opin Investig Drugs. 2013 Jul;22(7):895-906. doi: 10.1517/13543784.2013.798641. Epub 2013 Jun 4. Review.

PMID:
23735075
20.

GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics.

Wada A.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1558-70. Review.

PMID:
19273146

Supplemental Content

Support Center